Charles Prince Net Worth

The estimated Net Worth of Charles Prince is at least $5.05 Milione dollars as of 14 December 2018. Mr. Prince owns over 2,000 units of Johnson & Johnson stock worth over $4,700,666 and over the last 19 years he sold JNJ stock worth over $0. In addition, he makes $344,979 as Independent Director at Johnson & Johnson.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Prince JNJ stock SEC Form 4 insiders trading

Charles has made over 6 trades of the Johnson & Johnson stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of JNJ stock worth $268,740 on 14 December 2018.

The largest trade he's ever made was buying 10,000 units of Johnson & Johnson stock on 31 July 2008 worth over $134,400. On average, Charles trades about 264 units every 53 days since 2006. As of 14 December 2018 he still owns at least 28,520 units of Johnson & Johnson stock.

You can see the complete history of Mr. Prince stock trades at the bottom of the page.

Charles Prince biography

Charles O. Prince III. J.D. serves as Independent Director of the Company. He has served as Chief Executive Officer of Citigroup Inc. (financial services) from 2003 to 2007 and as Chairman from 2006 to 2007. Previously, he served as Chairman and Chief Executive Officer of Citigroup's Global Corporate and Investment Bank from 2002 to 2003, Chief Operating Officer from 2001 to 2002 and held positions of increasing responsibility since joining Commercial Credit Company, a predecessor to Citigroup, in 1979. Mr. Prince began his career as an attorney at U.S. Steel Corporation in 1975. Mr. Prince is a Director of Lord Abbett Family of Funds and a member of the Council on Foreign Relations and The Council of Chief Executives.

What is the salary of Charles Prince?

As the Independent Director of Johnson & Johnson, the total compensation of Charles Prince at Johnson & Johnson is $344,979. There are 14 executives at Johnson & Johnson getting paid more, with Alex Gorsky having the highest compensation of $25,365,800.

How old is Charles Prince?

Charles Prince is 70, he's been the Independent Director of Johnson & Johnson since 2006. There are no older and 31 younger executives at Johnson & Johnson.

What's Charles Prince's mailing address?

Charles's mailing address filed with the SEC is ONE JOHNSON & JOHNSON PLAZA, , NEW BRUNSWICK, NJ, 08933.

Insiders trading at Johnson & Johnson

Over the last 21 years, insiders at Johnson & Johnson have traded over $59,929,946 worth of Johnson & Johnson stock and bought 21,998 units worth $2,578,685 . The most active insiders traders include Hubert Joly, Anne M Mulcahy e Alex Gorsky. On average, Johnson & Johnson executives and independent directors trade stock every 21 days with the average trade being worth of $4,572,436. The most recent stock trade was executed by Robert J Decker on 30 August 2024, trading 5,635 units of JNJ stock currently worth $563,838.

What does Johnson & Johnson do?

Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.

Complete history of Mr. Prince stock trades at Johnson & Johnson e Xerox Corp

Johnson & Johnson executives and stock owners

Johnson & Johnson executives and other stock owners filed with the SEC include:

• Alex Gorsky,
  Chairman of the Board, Chief Executive Officer
• Paulus Stoffels,
  Vice Chairman- Executive Committee, Chief Scientific Officer
• Joaquin Duato,
  Vice Chairman - Executive Committee
• Joseph Wolk,
  Chief Financial Officer, Executive Vice President
• Jennifer Taubert,
  Executive Vice President - Worldwide Chairman, Pharmaceuticals
• Michael Ullmann,
  Executive Vice President, General Counsel
• Alex Gorsky,
  Exec. Chairman
• Peter Fasolo,
  Chief Human Resource Officer, Executive Vice President
• Dr. Paulus A. Stoffels M.D., Ph.D.,
  Chief Scientific Officer
• Joaquin Duato,
  CEO & Director
• Joseph J. Wolk CPA,
  Exec. VP & CFO
• Joseph J. Wolk C.P.A.,
  Exec. VP & CFO
• Jennifer L. Taubert,
  Exec. VP & Worldwide Chairman of Pharmaceuticals
• Anne Mulcahy,
  Lead Independent Director
• Charles Prince,
  Independent Director
• Mary Beckerle,
  Independent Director
• Ronald Williams,
  Independent Director
• D. Scott Davis,
  Independent Director
• A. Eugene Washington,
  Independent Director
• Jennifer Doudna,
  Independent Director
• Mark McClellan,
  Independent Director
• Ian Davis,
  Independent Director
• Marillyn Hewson,
  Independent Director
• Mark Weinberger,
  Independent Director
• Hubert Joly,
  Independent Director
• Christopher DelOrefice,
  Vice President, Investor Relations
• Kathryn Wengel,
  Executive Vice President, Chief Global Supply Chain Officer
• Michael Sneed,
  Executive Vice President - Global Corporate Affairs and Chief Communication Officer
• Thibaut Mongon,
  Executive Vice President, Worldwide Chairman, Consumer
• Ashley McEvoy,
  Executive Vice President - Worldwide Chairman, Medical Devices
• Dr. Guy J. Lebeau M.D.,
  Group Chairman of MD&D Bus. - EMEA
• Dr. Peter M. Fasolo Ph.D.,
  Exec. VP & Chief HR Officer
• Michael H. Ullmann,
  Exec. VP & Gen. Counsel
• Jessica Moore,
  VP of Investor Relations
• Ashley Watson,
  Chief Compliance Officer
• James Swanson,
  Exec. VP & Global CIO
• Robert J. Decker Jr.,
  Controller & Chief Accounting Officer
• James Cullen,
  Director
• Stephen J Cosgrove,
  
• Leo F Mullin,
  Director
• Michael M E Johns,
  Director
• Robert J Decker,
  VP Corporate Controller
• Elizabeth Forminard,
  Executive VP, General Counsel
• Ronald A Kapusta,
  Controller, CAO
• Susan L Lindquist,
  Director
• Gary J Pruden,
  Exec VP, WW Chair, Med Devices
• William D Perez,
  Director
• Jorge S. Mesquita,
  Exec VP, WW Chair, Consumer
• Dominic J Caruso,
  Chief Financial Officer
• Timothy Schmid,
  EVP, WW Chair, MedTech
• Mary Sue Coleman,
  Director
• David Satcher,
  Director
• William C Weldon,
  Chairman/CEO
• Arnold G Langbo,
  Director
• Russell C Deyo,
  Vice President, Administration
• Kaye I Foster Cheek,
  VP, Human Resources
• Colleen A Goggins,
  Member, Executive Committee
• Sherilyn S Mc Coy,
  Member, Executive Committee
• Donald M Jr. Casey,
  Member, Executive Committee
• Nicholas J Valeriani,
  Vice President,Human Resources
• Christine A Poon,
  Executive Committee Member
• Joseph C Scodari,
  Executive Committee Member
• Steven Reinemund,
  Director
• Ann Dibble Jordan,
  Director
• Robert J Darretta,
  Member, Executive Committee
• Per A Peterson,
  Executive Committee Member
• Michael J Dormer,
  Member, Executive Committee
• Joann Heffernan Heisen,
  Member, Executive Committee
• Gerard N Burrow,
  Director
• Henry B Schacht,
  Director
• M Judah Folkman,
  Director
• Roger S Fine,
  Vice President General Counsel
• James T Lenehan,
  Vice Chairman
• Brian D Perkins,
  Executive Committee Member
• Robert N Wilson,
  
• Nadja West,
  Director
• Vanessa Broadhurst,
  EVP, Global Corp Affairs
• Mathai Mammen,
  EVP, Pharm, R&D
• William Hait,
  EVP, Chief EI and Med Officer
• Darius Adamczyk,
  Director
• James D. Swanson,
  EVP, CIO
• John C Reed,
  EVP, Innovative Medicine, R&D
• Paula A Johnson,
  Director
• Eugene A. Woods,
  Director